Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 24, 2021
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
[ Wed, Mar 24th 2021
] - WOPRAI
Tue, March 23, 2021
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
[ Tue, Mar 23rd 2021
] - WOPRAI
Matthew Harrison Maintained (ADCT) at Buy with Decreased Target to $55 on, Mar 23rd, 2021
Matthew Harrison of Morgan Stanley, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $56 to $55 on, Mar 23rd, 2021.
Matthew has made no other calls on ADCT in the last 4 months.
There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Konstantinos Aprilakis of "Stifel" Initiated at Hold and Held Target at $42 on, Thursday, December 3rd, 2020
This is the rating of the analyst that currently disagrees with Matthew
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $48 on, Friday, March 19th, 2021
